These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28138258)

  • 1. Chidamide in the treatment of peripheral T-cell lymphoma.
    Chan TS; Tse E; Kwong YL
    Onco Targets Ther; 2017; 10():347-352. PubMed ID: 28138258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.
    Lu X; Ning Z; Li Z; Cao H; Wang X
    Intractable Rare Dis Res; 2016 Aug; 5(3):185-91. PubMed ID: 27672541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
    Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
    Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chidamide tablets: HDAC inhibition to treat lymphoma.
    Xu Y; Zhang P; Liu Y
    Drugs Today (Barc); 2017 Mar; 53(3):167-176. PubMed ID: 28447074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.
    Liu W; Zhao D; Liu T; Niu T; Song Y; Xu W; Jin J; Cai Q; Huang H; Li Z; Hou M; Zhang H; Zhou J; Hu J; Shen J; Shi Y; Yang Y; Zhang L; Zhao W; Ding K; Qiu L; Tan H; Zhang Z; Liu L; Wang J; Xu B; Zhou H; Gao G; Xue H; Bai O; Feng R; Huang X; Yang H; Yan X; Zeng Q; Liu P; Li W; Mao M; Su H; Wang X; Xu J; Zhou D; Zhang H; Ma J; Shen Z; Zhu J
    Front Oncol; 2021; 11():750323. PubMed ID: 34804937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.
    Chen J; Zuo Z; Gao Y; Yao X; Guan P; Wang Y; Li Z; Liu Z; Hong JH; Deng P; Chan JY; Cheah DMZ; Lim J; Chai KXY; Chia BKH; Pang JWL; Koh J; Huang D; He H; Sun Y; Liu L; Liu S; Huang Y; Wang X; You H; Saraf SA; Grigoropoulos NF; Li X; Bei J; Kang T; Lim ST; Teh BT; Huang H; Ong CK; Tan J
    Clin Epigenetics; 2023 Feb; 15(1):19. PubMed ID: 36740715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
    Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
    Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
    Dong M; Ning ZQ; Xing PY; Xu JL; Cao HX; Dou GF; Meng ZY; Shi YK; Lu XP; Feng FY
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1413-22. PubMed ID: 22362161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
    Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
    Guan W; Jing Y; Dou L; Wang M; Xiao Y; Yu L
    Leuk Lymphoma; 2020 Apr; 61(4):855-861. PubMed ID: 31755348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report.
    Wang XT; Guo W; Sun M; Han W; Du ZH; Wang XX; Du BB; Bai O
    World J Clin Cases; 2020 Jul; 8(14):3122-3129. PubMed ID: 32775395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
    Wang Y; Zhang M; Song W; Cai Q; Zhang L; Sun X; Zou L; Zhang H; Wang L; Xue H
    Am J Hematol; 2022 May; 97(5):623-629. PubMed ID: 35170082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
    Rai S; Kim WS; Ando K; Choi I; Izutsu K; Tsukamoto N; Yokoyama M; Tsukasaki K; Kuroda J; Ando J; Hidaka M; Koh Y; Shibayama H; Uchida T; Yang DH; Ishitsuka K; Ishizawa K; Kim JS; Lee HG; Minami H; Eom HS; Kurosawa M; Lee JH; Lee JS; Lee WS; Nagai H; Shindo T; Yoon DH; Yoshida S; Gillings M; Onogi H; Tobinai K
    Haematologica; 2023 Mar; 108(3):811-821. PubMed ID: 36200417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
    Gu R; Liu T; Zhu X; Gan H; Wu Z; Li J; Zheng Y; Dou G; Meng Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1000():181-6. PubMed ID: 26245362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
    Wen T; Sun G; Jiang W; He X; Shi Y; Ma F; Liu P
    EBioMedicine; 2023 Jan; 87():104420. PubMed ID: 36592514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
    Makita S; Maeshima AM; Maruyama D; Izutsu K; Tobinai K
    Onco Targets Ther; 2018; 11():2287-2293. PubMed ID: 29719411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports.
    Liu TZ; Zheng YJ; Zhang ZW; Li SS; Chen JT; Peng AH; Huang RW
    World J Clin Cases; 2020 Apr; 8(7):1278-1286. PubMed ID: 32337203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.